Immunology · ImmunosuppressantRegulatory Approvalcommercialmid-term

Aurobindo Pharma's Mycophenolate Mofetil ANDA217828 Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/2/2026, 12:31:17 AM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's Abbreviated Approval of Aurobindo Pharma's Mycophenolate Mofetil signals increased competition in the immunosuppressant market. This development necessitates a reassessment of pricing and market share strategies by existing players to maintain their competitive positioning. Regulatory context from FDA (FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (14 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for Mycophenolate Mofetil. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Immunology · Immunosuppressant, 8 regulatory and 6 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval allows Aurobindo to enter the market for Mycophenolate Mofetil, potentially increasing competition against existing suppliers.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — MYCOPHENOLATE MOFETIL (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA requirements, but does not suggest immediate regulatory challenges for existing products.

Key Risks

Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Aurobindo's entry could pressure pricing and market share for current suppliers, potentially impacting revenue streams in the immunosuppressant segment.
Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for Mycophenolate Mofetil.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any potential market responses from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalsmedium relevance
Moderate corpus alignment
Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalsmedium relevance
Moderate corpus alignment

Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma

Commercial impact

medium

Aurobindo's entry could pressure pricing and market share for current suppliers, potentially impacting revenue streams in the immunosuppressant segment.

Regulatory impact

low

The approval status indicates compliance with FDA requirements, but does not suggest immediate regulatory challenges for existing products.

What to watch

Monitor for the launch timeline and any potential market responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.